logo
  

Youdao Q4 Net Income From Cont. Ops. Rises - Quick Facts

Youdao, Inc. (DAO) reported fourth quarter net income from continuing operations attributable to shareholders of RMB 56.5 million, compared with RMB 12.3 million, last year. Net income from continuing operations per ADS was RMB 0.47 compared with RMB 0.10. Non-GAAP net income from continuing operations attributable to shareholders was RMB 69.3 million compared with RMB 31.1 million, last year. Non-GAAP net income from continuing operations per ADS was RMB 0.58 compared with RMB 0.25.

Fourth quarter net revenues were RMB 1.5 billion, a 1.8% increase from the same period in 2022.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Ride-hailing and delivery platform Uber Technologies, Inc. (UBER) reported Wednesday a net loss for the first quarter that sharply widened from last year, hurt by a huge net unrealized loss related to the revaluation of Uber's equity investments. Loss per share for the quarter missed analysts' expectations, while quarterly revenues topped it. Shares of Siemens Energy AG were gaining more than 12 percent in German trading after the company on Wednesday raised its outlook for fiscal 2024 after reporting a profit in its second quarter, compared to last year's loss, amid positive market environment. Meanwhile, second-quarter orders were lower than last year, and the company maintained annual earnings forecast. AstraZeneca, a major provider of Covid-19 vaccines across the world mainly during the initial pandemic period, has initiated a process to withdraw its Vaxzevria COVID-19 vaccine worldwide, citing weak demand and the surplus availability of new vaccines. Meanwhile, AstraZeneca reportedly had admitted recently in court documents that the vaccine could cause side-effects such as blood clots...

This week, we feature J&J’s Talc litigation closure,Emergent’s strategic changes for growth ,Pfizer’s breakthrough hemophilia B gene therapy approval,Novartis’s strategic Mariana Oncology Buyout, and Beyfortus Breakthrough RSV prevention.

View More Videos
RELATED NEWS
Follow RTT